Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation

• Published in: Pharmaceutics Vol. 14; no. 2
• Main Authors: Pressiat, Claire, Kudela, Agathe, de Roux, Quentin, Khoudour, Nihel, Alessandri, Claire, Haouache, Hakim, Vodovar, Dominique, Woerther, Paul-Louis, Hutin, Alice, Ghaleh, Bijan, Hulin, Anne, Mongardon, Nicolas
• Format: Journal Article
• Language: English
• Published: MDPI 01.02.2022
• Subjects: Life Sciences; Toxicology; amikacin; pharmacokinetic/pharmacodynamic modeling; extracorporeal membrane oxygenation; Bayesian modelization; sepsis; therapeutic drug monitoring; population pharmacokinetics
• DOI: 10.3390/pharmaceutics14020289
• ISSN: 1999-4923

Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these patients. We aimed to describe amikacin pharmacokinetics on V-A ECMO support and to determine relevant variables to improve its dosing. All critically ill patients requiring empirical antimicrobial therapy, including amikacin for nosocomial sepsis supported or not by V-A ECMO, were included in a prospective population pharmacokinetic study. This population pharmacokinetic analysis was built with a dedicated software, and Monte Carlo simulations were performed to identify doses achieving therapeutic plasma concentrations. Thirty-nine patients were included (control n = 15, V-A ECMO n = 24); 215 plasma assays were performed and used for the modeling process. Patients received 29 (24–33) and 32 (30–35) mg/kg of amikacin in control and ECMO groups, respectively. Data were best described by a two-compartment model with first-order elimination. Inter-individual variabilities were observed on clearance, central compartment volume (V1), and peripherical compartment volume (V2). Three significant covariates explained these variabilities: Kidney Disease Improving Global Outcomes (KDIGO) stage on amikacin clearance, total body weight on V1, and ECMO support on V2. Our simulations showed that the adequate dosage of amikacin was 40 mg/kg in KDIGO stage 0 patients, while 25 mg/kg in KDIGO stage 3 patients was relevant. V-A ECMO support had only a secondary impact on amikacin pharmacokinetics, as compared to acute kidney injury.